
CareDx (CDNA) Stock Forecast & Price Target
CareDx (CDNA) Analyst Ratings
Bulls say
CareDx is experiencing strong financial results and growth in the transplant testing industry, with expansions through partnerships and acquisitions. The company has set ambitious financial targets, recently announced a new COO/CFO, and has a strong balance sheet, though lower profit margins are projected for 2027. The company's future success will also rely on the success of their new diagnostic solutions and competition from potential competitors such as Natera.
Bears say
CareDx is likely to continue to face challenges in gaining adoption and revenue growth due to the slow adoption of new products by clinicians and healthcare administrators. Despite positive developments such as the MXD acquisition and favorable LCD update, CareDx's financial targets may still be overly ambitious and require continued reliance on inorganic growth and potential capital raises. Additionally, the company's testing services are under scrutiny and may face further restrictions, leading to potential revenue declines.
This aggregate rating is based on analysts' research of CareDx and is not a guaranteed prediction by Public.com or investment advice.
CareDx (CDNA) Analyst Forecast & Price Prediction
Start investing in CareDx (CDNA)
Order type
Buy in
Order amount
Est. shares
0 shares